<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="and autoimmune conditions. We propose that the immunomodulatory effect of" exact="hydroxychloroquine" post="also may be useful in controlling the cytokine storm"/>
 <result pre="Currently, there is no evidence to support the use of" exact="hydroxychloroquine" post="in SARS-CoV-2 infection. Methods The pharmacological activity of chloroquine"/>
 <result pre="of hydroxychloroquine in SARS-CoV-2 infection. Methods The pharmacological activity of" exact="chloroquine" post="and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells."/>
 <result pre="in SARS-CoV-2 infection. Methods The pharmacological activity of chloroquine and" exact="hydroxychloroquine" post="was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic"/>
 <result pre="by integrating their in vitro data. Using the PBPK models," exact="hydroxychloroquine" post="concentrations in lung fluid were simulated under 5 different"/>
 <result pre="Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than" exact="chloroquine" post="(EC50=5.47 μM) in vitro. Based on PBPK models results,"/>
 <result pre="results, a loading dose of 400 mg twice daily of" exact="hydroxychloroquine" post="sulfate given orally, followed by a maintenance dose of"/>
 <result pre="SARS-CoV-2 infection, as it reached three times the potency of" exact="chloroquine" post="phosphate when given 500 mg twice daily 5 days"/>
 <result pre="advance. Conclusions Hydroxychloroquine was found to be more potent than" exact="chloroquine" post="to inhibit SARS-CoV-2 in vitro. Chloroquine Hydroxychloroquine SARS-CoV-2"/>
</results>
